Pedro Alvarez, DO
Family Medicine · Hialeah, FLNPI 1417945619
Payments from drug & device makers
Across 301 payments — averaging $19.36 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$908
- GSK$872
- Boehringer Ingelheim$378
- Amgen$369
- Lilly USA, LLC$324
- plus $2K from 29 others
What the payments were for
- Food & beverage$5,73998%
- Education$291%
- Gifts$591%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 58 | $1,138 |
| AstraZeneca | 43 | $908 |
| GSK | 57 | $872 |
| Boehringer Ingelheim | 17 | $378 |
| Amgen | 19 | $369 |
| Lilly USA, LLC | 18 | $324 |
| Kowa Pharmaceuticals America, Inc. | 12 | $215 |
| Amarin Pharma, Inc. | 12 | $204 |
| Novo Nordisk | 10 | $188 |
| Phathom Pharmaceuticals, Inc. | 6 | $171 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $98 |
| Coloplast | 1 | $94 |
| Astellas Pharma US Inc | 5 | $90 |
| Merck | 4 | $78 |
| Johnson & Johnson(2 entities) | 4 | $71 |
| Redhill Biopharma Inc. | 3 | $67 |
| Mannkind Corporation | 1 | $59 |
| Phadia US Inc. | 3 | $58 |
| Bayer | 2 | $48 |
| Abbott | 2 | $43 |
| Nestle Healthcare Nutrition Inc. | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 2 | $34 |
| Sanofi-aventis U.S. LLC | 2 | $30 |
| Edwards Lifesciences | 1 | $30 |
| Amneal Pharmaceuticals LLC | 2 | $29 |
| Exact Sciences | 1 | $25 |
| Esperion Therapeutics, Inc. | 1 | $22 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| IBSA Pharma Inc. | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
| Pfizer | 1 | $19 |
| Dexcom, Inc. | 1 | $18 |
| Laborie Medical Technologies Corp. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Novartis | 1 | $14 |
How this compares
$5,828 in reported general payments places this provider in the 85th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 23 | $69,141 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $41,581 |
| OzempicSemaglutide | 31 | $41,343 |
| JardianceEmpagliflozin | 29 | $38,821 |
| FarxigaDapagliflozin Propanediol | 35 | $33,866 |
| TrulicityDulaglutide | 24 | $33,770 |
| MyrbetriqMirabegron | 23 | $22,060 |
| LinzessLinaclotide | 37 | $20,603 |
| JanuviaSitagliptin Phosphate | 22 | $20,103 |
| SynthroidLevothyroxine Sodium | 153 | $18,469 |
| VascepaIcosapent Ethyl | 26 | $18,377 |
| LivaloPitavastatin Calcium | 19 | $14,091 |
| EliquisApixaban | 15 | $11,664 |
| Azelastine Hcl | 167 | $6,066 |
| Famotidine | 175 | $3,873 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Linzess, Synthroid | $1,138 | $108,212213 claims |
| GSKTrelegy Ellipta | $872 | $41,58145 claims |
| Novo NordiskOzempic | $188 | $41,34331 claims |
| Boehringer IngelheimJardiance | $378 | $38,82129 claims |
| AstraZenecaFarxiga, Symbicort | $908 | $36,17346 claims |
| Lilly USA, LLCTrulicity | $324 | $33,77024 claims |
| Astellas Pharma US IncMyrbetriq | $90 | $22,06023 claims |
| MerckJanuvia | $78 | $20,10322 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $215 | $14,09119 claims |
| PfizerEliquis, Paxlovid | $19 | $13,09330 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $29 | $1,531152 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Hialeah
- Dario AltamiranoHialeah$15.5M
- Hugh ColemanDaytona Beach$115.5M
- Alexander WhiteDaytona Beach$69.7M
- Ronald SurowitzJupiter$38.3M
- Bruce RankinDeland$36.7M
- Keila HooverMiami$33.7M
- John NardandreaOcala$30.8M
- Jorge CasoMiami$22.6M
- Sharrell CooperPalm Coast$16.9M
- Christopher GallowayMelbourne$15.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.